Hospira Announces New Propofol Recall

Hospira announced a nationwide recall of seven lots of Propofol Injection Emulsion, 1 percent, 200 mg/20 mL to the user level due to a glass defect located on the interior neck of the vial, according to an FDA report.

Advertisement

A glass vial was identified during a routine inspection to contain visible embedded medial matriculate and free-floating metal particulates. Injecting the particulate matter could cause local inflammation, phlebitis, and/or low level allergic response through mechanical disruption of tissue or immune response to the particulate.

The report advises customers to check inventory and immediately quarantine any affected product.

More Articles on Surgery Centers:
10 Things to Know About Spine in ASCs

6 Key Observations for ASCs Today

ASC M&A Activity: 4 Big Trends for 2014

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.